The 145 references in paper V. ERMOLENKO M., N. FILATOVA N., A. NIKOLAEV Y., В. ЕРМОЛЕНКО М., Н. ФИЛАТОВА Н., А. НИКОЛАЕВ Ю. (2011) “ИНГИБИЦИЯ РЕНИН-АНГИОТЕНЗИН-АЛЬДОСТЕРОНОВОЙ СИСТЕМЫ И НЕФРОПРОТЕКЦИЯ // INHIBITION OF RENNIN-ANGIOTENSIN-ALDOSTERONE SYSTEM AND NEPHROPROTECTION” / spz:neicon:nefr:y:2011:i:2:p:30-42

1
Levitan D, Massry SG, Romoff M, Campese VM. Plasma catecholamines and autonomic nervous system function in patients with early renal insufficiency and hypertension: effect of clonidine. Nephron 1984; 36: 24–29
(check this in PDF content)
2
Лифшиц НЛ, Кутырина ИМ. Роль ренин-ангиотензиновой системы в патогенезе артериальной гипертензии при хронической почечной недостаточности. Тер архив 1998; (6): 64–67
(check this in PDF content)
3
Карабаева АЖ, Смирнов АВ, Каюков ИГ, Есаян АМ. Ренин-ангиотензин-альдостероновая система при хронической болезни почек. Нефрология 2006; (3): 43–48
(check this in PDF content)
4
Lonn ЕM, Yusuf S, Jha Р et al. Emerging role of angiotensin–converting enzyme inhibitors in cardiac and vascu1ar protection. Circulation 1994; 90: 2056–2069
(check this in PDF content)
5
Dzau V, Berustein K, Celermaier D et al. The relevance of fissure angiotensin–converting enzyme: manifestations in mechanistic and endpoint data. Am J Cardial 2001; 88 [Suppl 1]: 1–20
(check this in PDF content)
6
Stier Jr CT, Chander PN, Rocha R et al. Aldosterone as a mediator in cardiovascular injury. Cardiol Rev 2002; 10(2): 97–107
(check this in PDF content)
7
Volpe M, Savoia C, De Paolis P et al. The renin– angiotensin system as a risk factor and therapeutic target for cardiovascular and renal disease. J Am Soc Nephrol 2002; 13 [Suppl. 3]: S173–S178
(check this in PDF content)
8
Rossi G, Boscaro M, Ronconi V, Funder JW. Aldosterone as a cardiovascular risk factor. Trends Endocrinol Metab 2005; 16: 104–107
(check this in PDF content)
9
Ferrario CM, Strawn WB. Role of the renin–angiotensin– aldosterone system and proinflammatory mediators in cardiovascular disease. Am J Cardiol 2006; 98: 121–128
(check this in PDF content)
10
Ruster C, Wolf G. Renin–angiotensin–aldosterone system and progression of renal disease. J Am Soc Nephrol 2006; 17: 2985–2991
(check this in PDF content)
11
Russo LM, Osicka TM, Bonnet F et al. Albuminuria in hypertension is linked to altered lysosomal activity and TGF– beta1 expression. Hypertension 2002; 39: 281–286
(check this in PDF content)
12
Pals DT, Masucci FD, Sipos F, Denning GS. A specific competitive antagonist of the vascular action of angiotensin II. Cirs Res 1971; 29: 664–672
(check this in PDF content)
13
Kang PM, Landau AJ, Eberhardt RT, Fishman WH. Angiotensin II receptor antagonists: a new approach to blockade of the renin–angiotensin system. Am Heart J 1994; 127: 1388–1401
(check this in PDF content)
14
Ondetti MA, Williams NJ, Sabo EF et al. Angiotensin– converting enzyme inhibitors from the venom of Bothrops jararaca. Isolation, elucidation of structure, and synthesis. Biochemistry 1971; 10: 4033–4039
(check this in PDF content)
15
Ondetti MA, Rubin B, Cushman DW. Design of specific inhibitors of angiotensin–converting enzyme: new class of orally active antihypertensive agents. Science 1977; 196: 441–444
(check this in PDF content)
16
Taguma Y, Kitamomot YK, Futaki G et al. Effect of captopril on heavy proteinuria in azotemic diabetes. N Engl J Med 1985; 313: 1617–1620
(check this in PDF content)
17
Bjorck S, Nyberg G, Mulec H et al. Beneficial effects of angiotensin converting enzyme inhibition on renal function in patients with diabetic nephropathy. BMJ 1986; 293: 471–474
(check this in PDF content)
18
Lewis EJ, Hunsicker LG, Bain RP, Rohde RD. The effect of angiotensin–converting enzyme inhibitors on diabetic nephropathy. The Collaborative Study Group. N Engl J Med
(check this in PDF content)
19
3; 329: 1456–1462 19. Coronel F, Hortal L, Naranjo P et al. Captopril, proteinuria and peritoneal protein leakage in diabetic patients. Nephron 1989; 51: 443
(check this in PDF content)
20
Parving HH, Hommel E, Damkjaer Nielsen M, Giese J. Effect of captopril on blood pressure and kidney function in normotensive insulin dependent diabetics with nephropathy. BMJ 1989; 299: 533–536
(check this in PDF content)
21
Ravid M, Lang R, Rachmani R, Lishner M. Long-term nephroprotective effect of angiotensin–converting enzyme inhibition in non–insulin–dependint diabetus mellitus. 7-year follow-up study. Arch Intern Med 1996; 156: 286–289
(check this in PDF content)
22
Ruilope LM. Renoprotection and rennin–angiotensin system blockade in diabetes mellitus. Am J Hypertens 1997; 10: 325–331
(check this in PDF content)
23
Parving HH, Mogensen CE, Jensen HA, Evrin PE. Increased urinary albumin excretion rate in benign essential hypertension. Lancet 1974; 1: 1190–1192
(check this in PDF content)
24
Yudkin JS, Forrest RD, Jackson CA. Microalbuminuria predicts cardiovascular disease in non–diabetic subjects. Lancet 1988; 2: 530–533
(check this in PDF content)
25
Ruilope LM, Alcazar JM, Rodicio JL. Renal consequences of arterial hypertension. J Hypertens 1992; 10 [Suppl 7]: S85–S90
(check this in PDF content)
26
Hakim R, Goldszer RC, Brenner BM. Hypertension and proteinuria: Long term sequela and uninephrectomy in humans. Kidney Int 1984; 25: 930–936
(check this in PDF content)
27
Coppo R, Amore A, Roccatello D et al. Microalbuminuria in single kidney patients: relationship with protein intake. Clin Nephrol 1988; 29 (5): 219–228
(check this in PDF content)
28
Нанчикеева МЛ, Козловская ЛВ, Фомин ВВ и др. Эндотелиальная дисфункция и ремоделирование внутрипочечных сосудов как основа формирования гипертонической нефропатии. Ультразвуковая и функциональная диагностика 2009; (5): 84–94
(check this in PDF content)
29
Ruggenenti P, Perna A, Ganeva M et al. Impact of blood pressure control and angiotensin–converting enzyme inhibitor therapy on new–onset microalbuminuria in type 2 diabetes: a post hoc analysis of the BENEDICT trial. J Am Soc Nephrol 2006; 17: 3472–3481
(check this in PDF content)
30
Shinosaki T, Miyai I, Nomura Y et al. Mechanisms underlying the ameliorative property of lisinopril in progressive mesangioproliferative nephritis. Nephron 2002; 91 (4): 719–729
(check this in PDF content)
31
Buemi M, Allegra A, Corica F et al. Effects of lisinopril administration on blood bcl–2 concentrations in patients with immunoglobulin A nephropathy. Clin Pharmacol Ther 1999; 65 (6): 649–652
(check this in PDF content)
32
The EUCLID Study Group. Randomised placebo– controlled trial of lisinopril in normotensive patients with insulin– dependent diabetes and normoalbuminuria or microalbuminuria. Lancet 1997; 349: 1787–1792
(check this in PDF content)
33
Morelli E, Loon N, Meye TW et al. Effects of converting– enzyme inhibition on barrier function in diabetic glomerulopathy. Diabetes 1990; 39 (1): 76–82
(check this in PDF content)
34
Медведева ТЮ. Влияние препаратов, блокирующих ренин-ангиотензиновую систему, на прогрессирование почечной недостаточности в клинике и эксперименте. Автореф. дис. ... канд. мед. наук. М., 2001
(check this in PDF content)
35
Gerstein HC, Mann JF, Yi Q et al. Albuminuria and risk of cardiovascular events, death, and heart failure in diabetic and nondiabetic individuals. JAMA 2001; 286: 421–426
(check this in PDF content)
36
Mann JF, Gerstein HC, Pogue J et al. Renal insufficiency as a predictor of cardiovascular outcomes and the impact of ramipril: the HOPE randomized trial. Ann intern Med 2001; 134: 629–636
(check this in PDF content)
37
Marre M, Lievre M, Chatellier G et al. Effects of low dose ramipril on cardiovascular and renal outcomes in patients with type 2 diabetes and raised excretion of urinary albumin: randomised, double blind, placebo controlled trial (the DIABHYCAR study). BMJ 2004; 328: 495–498
(check this in PDF content)
38
Ruggenenti P, Perna A, Remuzzi G. ACE inhibitors to prevent End-stage Renal Disease: when to start and why possibly never stop: a post–hoc analysis of the REIN trial results. J Am Soc Nephrol 2001; 12: 2832–2837
(check this in PDF content)
39
Lewis E, Hunsicker L, Clarke W et al. Renoprotective effect of the angiotensin–receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med 2001; 345: 851–860
(check this in PDF content)
40
Parving HH, Lehnert H, Brochner–Mortensen J et al. Irbesartan in patients with type 2 diabetes and microalbuminuria study group. The effect of Irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes. N Engl J Med 2001; 345: 870–878.
(check this in PDF content)
41
Bramlage P, Pittrow D, Kirch W. The effect of irbesartan in reducing cardiovascular risk in hypertensive type 2 diabetic patients: an observational study in 16,600 patients in primary care. Curr Med Res Opin 2004; 20: 1625–1631
(check this in PDF content)
42
Makino H, Haneda M, Babazono T et al. Prevention of transition from incipient to overt nephropathy with telmisartan in patients with type 2 diabetes. Diabetes Care 2007; 30: 1577– 1578
(check this in PDF content)
43
Brenner BM, Cooper ME, de Zeeuw D et al. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 2001; 345: 861–869
(check this in PDF content)
44
Zeeuw D, Remuzzi G, Parving HH et al. Proteinuria, a target for renoprotection in patients with type 2 diabetic nephropathy: Lessons from RENAAL. Kidney Int 2004; 65: 2309– 2320
(check this in PDF content)
45
Viberti G, Wheeldon NM. Microalbuminuria reduction with valsartan in patients with type 2 diabetes mellitus. A blood pressure–independent effect. Circulation 2002; 106: 672–678
(check this in PDF content)
46
Ibsen H, Olsen MH, Wachtell K et al. Reduction in Albuminuria Translates to Reduction in Cardiovascular Events in Hypertensive Patients. Hypertension 2005; 45: 198–202
(check this in PDF content)
47
Цветкова ОА, Мустафина МХ. Органопротективные возможности и безопасность блокаторов рецепторов ангиотензина II. РМЖ 2009; 17 (8): 600–606
(check this in PDF content)
48
Jafar TH, Stark PC, Schmid CH et al. Progression of chronic kidney disease: the role of blood pressure control, proteinuria, and angiotensin–converting enzyme inhibition: a patient–level meta–analysis. Ann Intern Med 2003; 139: 244– 252
(check this in PDF content)
49
Maschio G, Alberti D, Locatelli F et al. Angiotensin– converting enzyme inhibitors and kidney protection: the AIPRI trial. The ACE Inhibition in Progressive Renal Insufficiency (AIPRI) Study Group. J Cardiovasc Pharmacol 1999; 33 [Suppl 1]: S16–S20
(check this in PDF content)
50
Casas JP, Chua W, Loukogeorgakis S et al. Effect of inhibitors of the renin–angiotensin system and other antihypertensive drugs on renal outcomes: systematic review and meta–analysis. Lancet 2005; 366: 2026–2033
(check this in PDF content)
51
Hou FF, Zhang X, Zhang GH et al. Efficacy and safety of benazepril for advanced chronic renal insufficiency. N Engl J Med 2006; 354: 131–140
(check this in PDF content)
52
Catapano F, Chiodini P, Nicola LD et al. Antiproteinuric response to dual blockade of the renin–angiotensin system in primary glomerulonephritis: meta–analysis and metaregression. Am J Kidney Dis 2008; 52: 475–485
(check this in PDF content)
53
Jennings DL, Kalus JS, Coleman CI et al. Combination therapy with an ACE inhibitor and an angiotensin receptor blocker for diabetic nephropathy: a meta–analysis. Diabet Med 2007; 24: 486–493
(check this in PDF content)
54
Bakris GL, Ruilope L, Locatelli F et al. Treatment of microalbuminuria in hypertensive subjects with elevated cardiovascular risk: results of the IMPROVE trial. Kidney Int 2007; 72: 879–885
(check this in PDF content)
55
Kunz R, Friedrich C, Wolbers M, Mann JF. Meta–analysis: effect of monotherapy and combination therapy with inhibitors of the renin–angiotensin system on proteinuria in renal disease. Ann Intern Med 2008; 148: 30–48
(check this in PDF content)
56
Agodoa LY, Appel L., Bakris GL et al. Effect of ramipril vs amlodipine on renal outcomes in hypertensive nephrosclerosis: a randomized controlled trial. JAMA 2001; 285: 2719–2728
(check this in PDF content)
57
Matos J, de Lourdes Rodriguez M, Ismerim V et al. Effects of dual blockade of the renin angiotensin system inhypertensive type 2 diabetic patients with nephropathy. Clin Nephrol 2005; 64: 180–189
(check this in PDF content)
58
Rossing K, Christensen PK, Jensen BR, Parving HH. Dual blockade of the renin–angiotensin system in diabetic nephropathy: a randomized double–blind crossover study. Diabetes Care 2002; 25: 95–100
(check this in PDF content)
59
Andersen NH, Poulsen PL, Knudsen ST et al. Long– term dual blockade with candesartan and lisinopril in hypertensive patients with diabetes. The CALM II study. Diabetes Care 2005; 28: 273–277
(check this in PDF content)
60
The ADVANCE Collaborative Group. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med 2008; 358: 2560–2572
(check this in PDF content)
61
Nakao M, Yoshimura A, Morita M et al. Combination treatment of angiotensin–II receptor blocker and angiotensin– converting–enzyme inhibitor in non–diabetic renal disease (COOPERATE): A randomised controlled trial. Lancet 2003; 361: 117–124
(check this in PDF content)
62
Fox KM. European trial on reduction of cardiac events with perindopril in stable coronary Artery disease Investigators. Lancet 2003; 362: 782–788
(check this in PDF content)
63
Ceconi С, Fох КM, Remme WJ et al. ACE inhibition with perindopril and endothelial function. Results of a substudy of the EUROPA study: PERTINEN. Cardiovasc Res 2007; 73 (1): 237–246
(check this in PDF content)
64
Heart Outcome Prevention Evaluation (HOPE) Study Investigators. Effect of ramipril on cardiovascular and microvascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy. Lancet 2000; 355: 253–259
(check this in PDF content)
65
Zanchetti A, Crepaldi G, Bond MG et al. Different effects of antihypertensive regimens based on fosinopril or hydrochlorothiazide with or without lipid lowering by pravastatin on progression of asymptomatic carotid atheroscle-rosis: principal results of PHYLLIS – a randomized double–blind trial. Stroke 2004; 35: 2807–2812
(check this in PDF content)
66
Borhani N, Mercuri M, Borhani P et al. Final outcome results of the Multicenter Isradipine Diuretic Atherosclerosis Study (MIDAS). A randomized controlled trial. JAMA 1996; 276: 785–791
(check this in PDF content)
67
Zanchetti A, Rose E, Dal Palo C et al. The Verapamil in Hypertension and Atherosclerosis Study (VHAS): results of long–term randomized treatment with either verapamil or chlorthalidone on carotid intima–media thickness. J Hypertens 1998; 16: 1667–1676
(check this in PDF content)
68
Zanchetti A, Bond MG, Hennig M et al. Calcium antagonist lacidipine slows down progression of asymptomatic carotid atherosclerosis. Principal Results of the European Lacidipine Study on Atherosclerosis (ELSA), a randomized, double–blind, long–term trial. Circulation 2002; 106: 2422–2427
(check this in PDF content)
69
Lisowska A, Musial W. Heart failure in patients with chronic kidney disease. Rocz Akad Med Bialymst 2004; 49: 162–165
(check this in PDF content)
70
Berger AK, Duval S, Manske C et al. Angiotensin– converting enzyme inhibitors and angiotensin receptor blockers in patients with congestive heart failure and chronic kidney disease. Am Heart J 2007; 153: 1064–1073
(check this in PDF content)
71
Диагностика и лечение артериальной гипертензии. Рекомендации Российского медицинского общества по артериальной гипертонии и Всероссийского научного общества кардиологов (третий пересмотр). Кардиоваскулярная терапия и профилактика 2008; 7 (6) (приложение 2): 1–30
(check this in PDF content)
72
K/DOQI clinical practice guidelines on hypertension and antihypertensive agents in chronic kidney disease. Am J Kidney Dis 2004; 43 [Suppl 1]: S1–S290
(check this in PDF content)
73
Lee VC, Rhew DC, Dylan M et al. Meta–analysis: angiotensin–receptor blockers in chronic heart failure and high–risk acute myocardial infarction. Ann Intern Med 2004; 141: 693–704
(check this in PDF content)
74
Pfeffer MA, McMurray JJ, Velazquez EJ et al. Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both. N Engl J Med 2003; 349: 1893–1906
(check this in PDF content)
75
Doulton TW, He FJ, MacGregor GA. Systematic review of combined angiotensin–converting enzyme inhibition and angiotensin receptor blockade in hypertension. Hypertension 2005; 45: 880–886
(check this in PDF content)
76
MacKinnon M, Shurraw S, Akbari A et al. Combination therapy with an angiotensin receptor blocker and an ACE inhibitor in proteinuric renal disease: a systematic review of the efficacy and safety data. Am J Kidney Dis 2006; 48: 8–20
(check this in PDF content)
77
Esteban V, Gallego–Delgado Y, Lazaro A et al. Long– term treatment with an ACE inhibitor or an AT1 antagonist avoids hypertension–induced inflammation in the kidney. J Nephrol 2006; 19: 725–731
(check this in PDF content)
78
Татарский БА, Казенова НВ, Серебряков НВ. Прямой локатор ренина при лечении пароксизмальной формы фибрилляции предсердий. Артериальная гипертензия 2010; 16 (1): 74–81
(check this in PDF content)
79
Jibrini MB, Molnar J, Arora RR. Prevention of atrial fibrillation by way of abrogation of the renin–angiotensin system: a systematic review and meta–analysis. Am J Ther 2008; 15: 36–43
(check this in PDF content)
80
Della Chiesa A, Pfiffner D, Meier B, Hess OM. Sexual activity in hypertensive man. J Hum Hypertens 2003; 17 (8): 515–521
(check this in PDF content)
81
Dusing R. Effect of the angiotensin II antagonist valsartan on sexual function in hypertensive men. Blood Pressure 2003; 12 [Suppl 2]: 29–34
(check this in PDF content)
82
Serebruany V, Popov A, Malinin A et al. Valsartan inhibits platelet activity in different doses in mild to moderate hypertension. Valsartan Inhibits Plateled (VIP) trial. Am Heart J 2006; 151: 92–99
(check this in PDF content)
83
Ridker PM, Danielson E, Rifai N, Glynn RJ. Valsartan, blood pressure reduction, and C–reactive protein: primary report of the Val–MARC trial. Hypertension 2006; 48 (1): 73–79
(check this in PDF content)
84
Cole BK, Keller SR, Wu R et al. Valsartan protects pancreatic islets and adipose tissue from inflammatory and metabolic consequences of a high–fat diet in mice. Hypertension 2010; 55 (3): 715–721
(check this in PDF content)
85
Ha T–S, Lee J–S, Hong E–J. Delay of renal progression in methylmalonic acidemia using angiotensin II inhibition: a case report. J Nephrol 2008; 21: 793–796
(check this in PDF content)
86
Melis D, Parenti G, Gatti R et al. Efficacy of ACE– inhibitor therapy on renal disease in glycogen storage disease type 1: a multicentre retrospective study. Clin Endocrinol 2005; 63: 19–25
(check this in PDF content)
87
Kitamura N, Matsukawa Y, Takei M, Sawada S. Antiproteinuric effect of angiotensin–converting enzyme inhibitors and an angiotensin II receptor blockers in patients with lupus nephritis. J Int Med Res 2009; 37 (3): 892–898
(check this in PDF content)
88
Chen S, Ge Y, Si J et al. Candesartan suppresses chronic renal inflammation by a novel antioxidant action independent of AT1R blockade. Kidney Int 2008; 74 (9): 1128–1138
(check this in PDF content)
89
Kjeldsen SE, McInnes GT, Mancia G et al. Progressive effects of valsartan compared with amlodipine in prevention of diabetes according to categories of diabetogenic risk in hypertensive patients: the VALUE trial. Blood Press 2008; 17: 170–177
(check this in PDF content)
90
Mochizuki S, Dahlof B, Shimizu M et al. Valsartan in a Japanese population with hypertension and other cardiovascular disease (Jikei Heart Study): a randomised, open–label, blinded endpoint morbidity–mortality study. Lancet 2007; 369: 1431–1439
(check this in PDF content)
91
Lithell H, Hansson L, Skoog I et al. The study on cognition and prognosis in the elderly (SCOPE): principal results of a randomized double–blind intervention trial. J Hypertens 2003; 21: 875–886
(check this in PDF content)
92
Schrader J, Luders S, Kulschewski A et al. The ACCESS Study: Evaluation of Acute Candesartan Cilexetil Therapy in Stroke Survivors. Stroke 2003; 34: 1699–1703
(check this in PDF content)
93
Bragulat E, Larrousse M, Coca A, de la Sierra A. Effect of long–term irbesartan treatment on endothelium–dependent vasodilation in essential hypertensive patients. Br J Biomed Sci 2003; 60: 191–196
(check this in PDF content)
94
Mak IT, Freedman AM, Dickens BF, Weglicki WB. Protective effects of sulfhydryl–containing angiotensin converting enzyme inhibitors against free radical injury in endothelial cells. Biochem Pharmacol 1990; 40(9): 2169–2175
(check this in PDF content)
95
Pasini AF, Garbin U, Uava MC et al. Effect of sulfhydryl and non–sulfhydril angiotensin–converting enzyme inhibitors in endothelial function in essential hypertensive patients. Am J Hypertens 2007; 20 (4): 443–450
(check this in PDF content)
96
Evangelista S, Manzini S. Antioxidant and cardioprotective properties of the sulfhydryl angiotensin convesting enzyme inhibitor zofenopril. J Int Med Res 2005; 33: 42–54
(check this in PDF content)
97
Mortensen EM, Restrepo M, Copeland L et al. Impact of previous statin and angiotensin II receptor blocker use on mortality in patients hospitalized with sepsis. Pharmacotherapy 2007; 27 (12): 1619–1626
(check this in PDF content)
98
Etminan M, Zhang B, Fitzgerald M, Brophy JM. Do angiotensin–converting enzyme inhibitors or angiotensin II receptor blockers decrease the risk of hospitalization secondary to community–acquired pneumonia? A nested case–cohort study. Pharmacotherapy 2006; 26: 476–482
(check this in PDF content)
99
Hay U, Ludvik B, Gisinger Ch, Schernthaner G. Fehlender Effekt der ACE–Inhibition auf die Makroproteinurie bei diabetischer Nephropathie – eine Langzeitstudie fiber 6 Monate. Schw Med Wochenschr 1988; 118 (5): 165–169
(check this in PDF content)
100
Julius S, Kjeldsen SE, Weber M et al. Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial. Lancet 2004; 363: 2022–2031
(check this in PDF content)
101
Niepen Patricia Van der, Woestenburg A, Brie H, et al. Effectiveness of Valsartan for Treatment of Hypertension: Patient Profiling and Hierarchical Modeling of Determinants and Outcomes (the PREVIEW Study). Ann Pharmacotherapy; 43 (5): 849–861
(check this in PDF content)
102
Solomon SD, Rice MM, Jablonski KA et al. Renal function and effectiveness of angiotensin–converting enzyme inhibitor therapy in patients with chronic stable coronary disease in the prevention of events with ACE inhibition (PEACE) trial. Circulation 2006; 114: 26–31
(check this in PDF content)
103
Velussi M, Brocco E, Frigato F et al. Effects of cilazapril and amlodipine on kidney function in hypertensive NIDDM patients. Diabetes 1996; 45: 216–222
(check this in PDF content)
104
Zucchelli P, Zuccala A, Borghi M et al. Long–term comparison between captopril and nifedipine in the progression of renal insufficiency. Kidney Int 1992; 42: 452–458
(check this in PDF content)
105
Rahman M, Pressel S, Davis BR et al. Renal outcomes in high–risk hypertensive patients treated with an angiotensin– converting enzyme inhibitor or a calcium channel blocker vs a diuretic: a report from the Antihypertensive and Lipid–Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). Arch Intern Med 2005; 165 (8): 936–946
(check this in PDF content)
106
The ALLHAT officers and coordinators for the ALLHAT collaborative research group. Major outcome in high–risk hypertensive patients randomized to angiotensin–converting enzyme inhibitor or calcium channel blоcker vs diuretic. The antihypertensive and lipid–lowering treatment to prevent heart attack trial (ALLHAT). JAMA 2002; 288: 2981–2997
(check this in PDF content)
107
Suissa S, Hutchinson T, Brophy J et al. ACE–inhibitor use and the long–term risk of renal failure in diabetes. Kidney Int 2006; 69: 913–919
(check this in PDF content)
108
Kent DM, Jafar TH, Hayward RA et al. Progression risk, urinary protein excretion, and treatment effects of angiotensin–converting enzyme inhibitors in nondiabetic kidney disease. J Am Soc Nephrol 2007; 18 (6): 1959–1965
(check this in PDF content)
109
Mann JF, Schmieder RE, McQueen M et al. Renal outcomes with telmisartan, ramipril, or both, in people at high vascular risk (the ONTARGET study): a multicentre, randomised, double–blind, controlled trial. Lancet 2008; 372: 547–553
(check this in PDF content)
110
Onuigbo MA, Onuigbo NT. Does renin–angiotensin aldosterone system blockade exacerbate contrast–induced nephropathy in patients with chronic kidney disease? A prospective 50–month Mayo Clinic study. Ren Fail 2008; 30 (1): 67–72
(check this in PDF content)
111
Griffin KA, Bidani AK. Progression of renal disease: renoprotective specificity of renin–angiotensin system blockade. Clin J Am Soc Nephrol 2006; 1:1054–1065
(check this in PDF content)
112
Tu rnbull F. Blood Pressure Lowering Treatment Trialists’ Collaboration. Effects of different blood–pressure– lowering regimens on major cardiovascular events: results of prospectively–designed overviews of randomised trials. Lancet 2003; 362: 1527–1535
(check this in PDF content)
113
Jafar TH, Schmid CH, Landa M et al. Angiotensin– converting enzyme inhibitors and progression of nondiabetic renal disease. A meta–analysis of patient–level data. Ann Intern Med 2001; 135: 73–87
(check this in PDF content)
114
Giatras I, Lau J, Levey AS. Angiotensin–converting– enzyme inhibition and progressive renal disease study group. Effects of angiotensin–converting enzyme inhibits on the progression of nondiabetic renal disease: meta–analysis of randomised trials. Ann Intern Med 1997; 127: 337–345
(check this in PDF content)
115
Strippoli GFM, Craig M, Deeks JJ et al. Effects of angiotensin converting enzyme inhibitors and angiotensin II receptor antagonists on mortality and renal outcomes in diabetic nephropathy: systematic review. BMJ 2004; 329: 828
(check this in PDF content)
116
Haynes R, Mason Ph, Rahimi K, Landray M. Dual blockade of the renin–angiotensin system: are two better than one? NDT 2009; 24: 3602–3607
(check this in PDF content)
117
Staessen JA, Wang J. Do ancillary properties of antihypertensive drugs explain the outcome results of recent trials? J Nephrol 2002; 15: 422–427
(check this in PDF content)
118
Phillips CO, Kashani A, Ko DK et al. Adverse effects of combination of angiotensin II receptor blockers plus angiotensin–converting enzyme inhibitors for left ventricular dysfunction: A quantitative review of data from randomized clinical trials. Arch Intern Med 2007; 167: 1930–1936
(check this in PDF content)
119
The ONTARGET Investigators. Telmisartan, ramipril, or both in patients at high risk for vascular events. N Engl J Med 2008; 358: 1547–1559
(check this in PDF content)
120
Sleight P, Redon J, Verdecchia P et al. Prognostic value of blood pressure in patients with high vascular risk in the Ongoing Telmisartan Alone and in combination with Ramipril Global Endpoint Trial study. J Hypertens 2009; 27: 1360–1369
(check this in PDF content)
121
Centers for Disease Control and Prevention (CDC): Prevalence of chronic kidney disease and associated risk factors – United States, 1999–2004. Morb Mortal Wkly Rep 2007; 56: 161–165
(check this in PDF content)
122
Centers for Disease Control and Prevention (CDC): Hospitalization discharge diagnoses for kidney disease – United States, 1980–2005. Morb Mortal Wkly Rep 2008; 57: 309–312
(check this in PDF content)
123
Epstein M. Re–examination RAS–blocking treatment regimens for abrogating progression of chronic kidney disease. Nat Clin Pract Nephrol 2009; 5: 12–13
(check this in PDF content)
124
Ruggenenti P, Remuzzi G. Is the ONTARGET renal substudy actually off target? Nat Rev Nephrol 2009; 5: 436–437
(check this in PDF content)
125
Abutaleb N. ONTARGET should not be over interpreted. NDT 2010; 25 (1): 44–47
(check this in PDF content)
126
D i Bari M, van de Poll–Franse L, Onder G et al. Antihypertensive medications and differences in muscle mass in older persons: the health, aging and body composition study. J Am Geriatr Soc 2004; 52: 961–996
(check this in PDF content)
127
Tobili JE, Stella I, Mazza ON et al. The effect of different anti hypertensive drugs on cavernous tissue in experimental chronic renal insufficiency. J Nephrol 2006; 19 (4): 419–428
(check this in PDF content)
128
Onuigbo M, Onuigbo N. Late–onset renal failure from angiotensin blockade (LORFFAB) in 100 CKD patients. Int Urol Nephrol 2008; 40: 233–239
(check this in PDF content)
129
Loriga G, Vidili G, Ruggenenti P et al. Renal hemodynamics and renoprotection. Nephron Clin Pract 2008; 110: 213–219
(check this in PDF content)
130
Ogata C, Kamide K, Suzuki Y et al. Evaluation of intrarenal hemodynamics by Doppler ultrasonography for renoprotective effect of angiotensin receptor blockade. Clin Nephrol 2005; 64: 352–357
(check this in PDF content)
131
Sozen AB, Kayacan MS, Tansel T et al. Drugs with blocking effects on the renin–angiotensin–aldosterone system do not improve endothelial dysfunction long–term in hypertensive patients. J internat Med Res 2009; 37: 996–1002
(check this in PDF content)
132
Ahmed A, Kamath N, Kossi M, Nahas A. The impact of stopping inhibitors of the renin-angiotensin system in patients with advanced chronic kidney disease. NDT 2010; 25: 3977– 3982
(check this in PDF content)
133
Адашева ТВ, Задионченко ВС, Павлов СВ и др. Органопротективные и плейотропные эффекты амлодипина у больных артериальной гипертензией и обструктивной болезнью легких. Сердце 2010; 9 (3): 165–171
(check this in PDF content)
134
Арутюнов ГП, Оганегзова ЛГ. Антагонисты кальциевых каналов и нефропротекция. Сердце: журнал для практикующих врачей 2010; 9 (3): 160–164
(check this in PDF content)
135
Derwa A, Peeters P, Vanholder R. Calcium Channel blockers in the prevention of end–stage renal disease: a review. Acta clinica belgica 2004; 59 (1): 44–56
(check this in PDF content)
136
Peng T, Hu Z, Xia Q et al. A comparative study of the renoprotective effects of benidipine and valsartan in primary hypertensive patients with proteinuria. Arzneimittelforschung 2009; 59 (12): 647–650
(check this in PDF content)
137
Renke M, Tylicki L, Rutkowski P et al. Effect of pentoxifylline on proteinuria, markers of tubular injury and oxidative stress in non–diabetic patients with chronic kidney disease – placebo controlled, randomized, cross–over study. Acta Biochim Pol 2010; 57 (1): 119–123
(check this in PDF content)
138
Kaysen GA, Gambertoglio J, Jimenez I et al. Effect of dietary protein intake on albumin homeostasis in nephrotic patients. Kidney Int 1986; 29: 572–577
(check this in PDF content)
139
Gansevoort RT, de Zeeuw D, de Jong PR. Additive antiproteinuric effect of ACE inhibition and a low–protein diet in human renal disease. Nephrol Dial Transplant 1995; 10: 497– 504
(check this in PDF content)
140
Sarafidis PA, Stafylas PC, Georgianos PI et al. Effect of Thiazolidinediones on Albuminuria and Proteinuria in Diabetes: A Meta–analysis. Am J Kidney Dis 2010; 55: 853–847
(check this in PDF content)
141
Blankestijn PJ. Sympathetic hyperactivity in chronic kidney disease. NDT 2004; 19 (6): 1354–1357
(check this in PDF content)
142
Orth SR, Schroeder T., Ritz E. Effects of smoking on renal function in patients with type 1 and type 2 diabetes mellitus. NDT 2005; 20: 2414–2419
(check this in PDF content)
143
Huang Y, Wongamorntham S, Kasting J et al. Renin increases mesangial cell transforming growth factor–в1 and matrix proteins through receptor–mediated, angiotensin II– independent mechanisms. Kidney Int 2006; 69: 13–15
(check this in PDF content)
144
Kushiro T, Itakura H, Abo Y et al. Aliskiren, a novel oral renin inhibitor provides dose–dependent efficacy and placebo– like tolerability in Japanese patients with hypertension. Hypertens Res 2006; 29: 997–1005
(check this in PDF content)
145
Parving HH, Persson F, Lewis JB, Hollenberg NK. AVOID Study Investigators. Aliskiren combined with losartan in type 2 diabetes and nephropathy. N Engl J Med 2008; 358: 2433–2446 Ïîñòóïèëà â ðåäàêöèþ 14.04.2011 ã.
(check this in PDF content)